权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Prx1 in malignant progression of prostate cancer

Prx1在前列腺癌恶性进展中的作用

基本信息

批准号：
7218563
负责人：
YOUNG-MEE PARK
金额：
$ 30.32万
依托单位：
ROSWELL PARK CANCER INSTITUTE CORP
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-04-05 至 2011-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7218563
关键词：
Address Affect Androgen Receptor Androgens Antioxidants Apoptosis Base Sequence Binding Biological Biological Assay Blood Vessels Cancer Etiology Cell Culture System Cell Hypoxia Cell Line Cell Proliferation Cell Survival Cells Cessation of life Chromatin Chronic Clinical Cloning Data Deletion Mutagenesis Deoxyribonuclease I Depth Development Dimerization EMSA Elements Elevation Employee Strikes Environment Family Gene Targeting Generations Genes Gleason Grade for Prostate Cancer Human Hypoxia In Vitro Knowledge Laboratories Ligand Binding Malignant - descriptor Malignant Neoplasms Malignant neoplasm of prostate Mediating Messenger RNA Metastatic Prostate Cancer Microelectrodes Molecular Molecular Profiling Monitor Neoplasm Metastasis Nuclear Nucleic Acid Regulatory Sequences Outcome Oxidation-Reduction Oxidative Stress PC3 cell line Pattern Personal Satisfaction Phenotype Printing Prostate Prostate Cancer therapy Prostate-Specific Antigen Protein Family Proteins Proteome Proteomics Reactive Oxygen Species Receptor Activation Regulation Research Research Personnel Resistance Role Second Primary Cancers Signaling Molecule Stress Sulfhydryl Compounds Testing Therapeutic Time Tissues Transcriptional Regulation base cancer cell cancer therapy chromatin immunoprecipitation clinically significant deprivation design foot human tissue in vivo mRNA Expression member men novel novel therapeutics oxidation peroxiredoxin pressure prognostic programs promoter receptor binding research study response sound transcription factor tumor tumor growth tumor progression

项目摘要

DESCRIPTION (provided by applicant): Prostate cancer is the most common noncutaneous cancer and the second leading cause of cancer death in men in the US. Recent studies demonstrated that prostate cancer cells grow in a chronic or transient hypoxic microenvironment. A correlation between the extent of tumor hypoxia and poor clinical outcome has also been demonstrated. More recently, androgen deprivation, the most common form of prostate cancer therapy, was itself shown to generate a state of transient hypoxia in prostate cancer. Two highly homologous members of the peroxiredoxin protein family, Prx1 and Prx2, have been shown to affect cell proliferation/apoptosis and increase the stress resistance in cancer cells. However, the effects of Prx expression in human cancers, their influence on cancer therapy, and the regulatory basis of their expression in cancer have not been investigated. Because these Prxs can be predicted to have a significant impact on prostate cancer, the investigator has recently undertaken studies of Prx1/2 in prostate cancer. The research proposed in this application emanates from our recent studies of Prx1/2 regulation and function in human prostate cancer cells and tissues. The observations made in the Pi's laboratory led us to postulate that Prx1 possesses unique functions and regulatory mechanisms in human prostate cancer that significantly influences its malignant progression. Our preliminary data described herein provide compelling support of this prediction. It is hypothesized that hypoxia-induced oxidative stress in tumors up-regulates Prx1 expression via activating the redox-sensitive transcriptional factors and signaling molecules and that the dysregulated activation of these regulatory components leads to a constitutive Prx1 elevation in a subset of cancer cells. It is also hypothesized that the elevated Prx1 in these cells provides them with aggressive survival phenotypes, in part by directly reducing ROS and oxidative damage, and also by increasing prostate specific antigen (PSA) expression and androgen receptor (AR) activity. It is further hypothesized that the functions of Prx1 are mediated by its ability to control the oxidation/function of redox-sensitive molecules that in turn contribute to the malignant progression of prostate cancer. Three Specific Aims are proposed to test these hypotheses. In Aim 1, we will establish the molecular basis for Prx1 elevation in human prostate cancer cells. In Aim 2, we will determine the functional significance of Prx1 in malignant progression of prostate cancer cells. In particular, we will investigate the novel role for Prx1 in regulating PSA expression and AR activity in response to hypoxia. In Aim 3, we will identify important redox-sensitive target/effecter molecules that mediate the Prx1 functions to promote malignant progression of prostate cancer. The objective of the proposed research is to define the role of Prx1 in hypoxia-response of prostate cancer and the underlying regulatory mechanisms involved. This study will also provide a sound scientific basis upon which the role of Prx1 can be elucidated in prostate cancer, enabling the development of novel prognostic/therapeutic approaches to inhibit its malignant progression.

描述（由申请人提供）：前列腺癌是最常见的非皮肤癌，也是美国男性癌症死亡的第二大原因。最近的研究表明，前列腺癌细胞在慢性或短暂的缺氧微环境中生长。肿瘤缺氧程度与不良临床结果之间的相关性也已得到证实。最近，雄激素剥夺（前列腺癌治疗最常见的形式）本身被证明会在前列腺癌中产生短暂的缺氧状态。过氧化还原蛋白家族的两个高度同源的成员 Prx1 和 Prx2 已被证明可以影响细胞增殖/凋亡并增加癌细胞的应激抵抗力。然而，Prx表达在人类癌症中的作用、它们对癌症治疗的影响以及它们在癌症中表达的调控基础尚未得到研究。由于这些 Prx 预计会对前列腺癌产生显着影响，因此研究人员最近开展了 Prx1/2 在前列腺癌中的研究。本申请中提出的研究源于我们最近对人前列腺癌细胞和组织中 Prx1/2 调节和功能的研究。 Pi实验室的观察结果使我们推测Prx1在人类前列腺癌中具有独特的功能和调节机制，显着影响其恶性进展。我们在此描述的初步数据为这一预测提供了令人信服的支持。据推测，肿瘤中缺氧诱导的氧化应激通过激活氧化还原敏感转录因子和信号分子上调 Prx1 表达，并且这些调节成分的激活失调导致一部分癌细胞中 Prx1 的组成性升高。还假设这些细胞中升高的 Prx1 为它们提供了积极的生存表型，部分是通过直接减少 ROS 和氧化损伤，以及增加前列腺特异性抗原 (PSA) 表达和雄激素受体 (AR) 活性。进一步假设 Prx1 的功能是由其控制氧化还原敏感分子的氧化/功能的能力介导的，而氧化还原敏感分子反过来又导致前列腺癌的恶性进展。提出了三个具体目标来检验这些假设。在目标 1 中，我们将建立人类前列腺癌细胞中 Prx1 升高的分子基础。在目标 2 中，我们将确定 Prx1 在前列腺癌细胞恶性进展中的功能意义。特别是，我们将研究 Prx1 在缺氧反应中调节 PSA 表达和 AR 活性的新作用。在目标 3 中，我们将鉴定介导 Prx1 功能以促进前列腺癌恶性进展的重要氧化还原敏感靶标/效应分子。本研究的目的是明确 Prx1 在前列腺癌缺氧反应中的作用以及所涉及的潜在调节机制。这项研究还将为阐明 Prx1 在前列腺癌中的作用提供坚实的科学基础，从而能够开发新的预后/治疗方法来抑制其恶性进展。